[ü]
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE
|
[
]
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE
|
Delaware
|
22-3436215
|
(State
or other jurisdiction of
|
(I.R.S.
Employer
|
incorporation
or organization)
|
Identification
No.)
|
Two
Greenville Crossing, 4001 Kennett Pike
|
19807
|
Suite
238, Greenville,
Delaware
|
(Zip
Code)
|
(Address
of principal executive offices)
|
For
the three months ended
|
For
the six months ended
|
|||||||||||||||
June
30,
|
June
30,
|
|||||||||||||||
Millions
of dollars
|
2007
|
2006
|
2007
|
2006
|
||||||||||||
Sales
and other operating revenues:
|
||||||||||||||||
Trade
|
$ |
146
|
$ |
133
|
$ |
280
|
$ |
260
|
||||||||
Related
parties
|
15
|
20
|
33
|
37
|
||||||||||||
161
|
153
|
313
|
297
|
|||||||||||||
Operating
costs and expenses:
|
||||||||||||||||
Cost
of sales
|
142
|
134
|
264
|
280
|
||||||||||||
Selling,
general and administrative expenses
|
22
|
11
|
34
|
22
|
||||||||||||
Research
and development expenses
|
1
|
1
|
2
|
2
|
||||||||||||
165
|
146
|
300
|
304
|
|||||||||||||
Operating
income (loss)
|
(4 | ) |
7
|
13
|
(7 | ) | ||||||||||
Interest
expense
|
(19 | ) | (19 | ) | (38 | ) | (31 | ) | ||||||||
Interest
income
|
6
|
1
|
7
|
2
|
||||||||||||
Other
income (expense), net
|
(16 | ) |
20
|
(16 | ) | (5 | ) | |||||||||
Income
(loss) from continuing operations before
equity
investment and income taxes
|
(33 | ) |
9
|
(34 | ) | (41 | ) | |||||||||
Income
from equity investment
in
Equistar Chemicals, LP
|
3
|
38
|
6
|
113
|
||||||||||||
Income
(loss) from continuing operations
before
income taxes
|
(30 | ) |
47
|
(28 | ) |
72
|
||||||||||
Provision
for (benefit from) income taxes
|
(13 | ) |
2
|
(12 | ) | (5 | ) | |||||||||
Income
(loss) from continuing operations
|
(17 | ) |
45
|
(16 | ) |
77
|
||||||||||
Income
from discontinued operations, net of tax
|
283
|
69
|
297
|
70
|
||||||||||||
Net
income
|
$ |
266
|
$ |
114
|
$ |
281
|
$ |
147
|
Millions
of dollars
|
June
30,
2007
|
December 31,
2006
|
||||||
ASSETS
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ |
33
|
$ |
76
|
||||
Accounts
receivable:
|
||||||||
Trade,
net
|
109
|
96
|
||||||
Related
parties
|
19
|
15
|
||||||
Inventories
|
92
|
87
|
||||||
Prepaid
expenses and other current assets
|
27
|
13
|
||||||
Deferred
tax assets
|
38
|
62
|
||||||
Notes
receivable from Equistar Chemicals, LP
|
500
|
-
-
|
||||||
Current
assets held for sale
|
-
-
|
661
|
||||||
Total
current assets
|
818
|
1,010
|
||||||
Property,
plant and equipment, net
|
121
|
129
|
||||||
Investment
in Equistar Chemicals, LP
|
446
|
470
|
||||||
Goodwill,
net
|
49
|
49
|
||||||
Other
assets, net
|
71
|
62
|
||||||
Long-term
assets held for sale
|
-
-
|
694
|
||||||
Total
assets
|
$ |
1,505
|
$ |
2,414
|
||||
LIABILITIES
AND STOCKHOLDER’S EQUITY
|
||||||||
Current
liabilities:
|
||||||||
Accounts
payable:
|
||||||||
Trade
|
$ |
72
|
$ |
84
|
||||
Related
parties
|
30
|
18
|
||||||
Accrued
liabilities
|
152
|
72
|
||||||
Current
liabilities associated with assets held for sale
|
-
-
|
335
|
||||||
Total
current liabilities
|
254
|
509
|
||||||
Long-term
debt
|
391
|
767
|
||||||
Other
liabilities
|
255
|
381
|
||||||
Deferred
income taxes
|
261
|
248
|
||||||
Long-term
liabilities associated with assets held for sale
|
-
-
|
361
|
||||||
Commitments
and contingencies
|
||||||||
Minority
interest
|
5
|
5
|
||||||
Stockholder’s
equity:
|
||||||||
Common
stock, $0.01 par value,
1,000 shares authorized, 709 shares issued
|
-
-
|
-
-
|
||||||
Additional
paid-in capital
|
1,176
|
1,176
|
||||||
Retained
deficit
|
(602 | ) | (840 | ) | ||||
Accumulated
other comprehensive loss
|
(145 | ) | (103 | ) | ||||
Treasury
stock, at cost (48 shares issued)
|
(90 | ) | (90 | ) | ||||
Total
stockholder’s equity
|
339
|
143
|
||||||
Total
liabilities and stockholder’s equity
|
$ |
1,505
|
$ |
2,414
|
For
the six months ended
June
30,
|
||||||||
Millions
of dollars
|
2007
|
2006
|
||||||
Cash
flows from operating activities:
|
||||||||
Net
income
|
$ |
281
|
$ |
147
|
||||
Income
from discontinued operations, net of tax
|
(297 | ) | (70 | ) | ||||
Adjustments
to reconcile net income to
cash provided by (used in) operating activities:
|
||||||||
Depreciation
and amortization
|
17
|
13
|
||||||
Equity
investment in Equistar Chemicals, LP –
|
||||||||
Amount
included in net income
|
(6 | ) | (113 | ) | ||||
Distributions
of earnings
|
6
|
89
|
||||||
Deferred
income taxes
|
38
|
(48 | ) | |||||
Debt
prepayment premiums and charges
|
14
|
7
|
||||||
Changes
in assets and liabilities that provided (used) cash:
|
||||||||
Accounts
receivable
|
(17 | ) |
12
|
|||||
Inventories
|
(5 | ) |
20
|
|||||
Accounts
payable
|
(1 | ) |
11
|
|||||
Other,
net
|
(129 | ) |
35
|
|||||
Net
cash provided by (used in) operating activities – continuing
operations
|
(99 | ) |
103
|
|||||
Net
cash used in operating activities – discontinued
operations
|
(120 | ) | (20 | ) | ||||
Net
cash provided by (used in) operating activities
|
(219 | ) |
83
|
|||||
Cash
flows from investing activities:
|
||||||||
Advances
under loan agreements to Equistar Chemicals, LP
|
(500 | ) |
-
-
|
|||||
Expenditures
for property, plant and equipment
|
(6 | ) | (5 | ) | ||||
Payments
to discontinued operations
|
(104 | ) | (32 | ) | ||||
Distributions
from affiliates in excess of earnings
|
24
|
-
-
|
||||||
Other
|
3
|
1
|
||||||
Net
cash used in investing activities – continuing operations
|
(583 | ) | (36 | ) | ||||
Net
proceeds from sale of discontinued operations
before required repayment of debt
|
1,089
|
-
-
|
||||||
Other
net cash provided by investing activities – discontinued
operations
|
89
|
9
|
||||||
Net
cash provided by (used in) investing activities
|
595
|
(27 | ) | |||||
Cash
flows from financing activities:
|
||||||||
Repayment
of long-term debt
|
(390 | ) | (241 | ) | ||||
Other
|
1
|
(1 | ) | |||||
Net
cash used in financing activities – continuing operations
|
(389 | ) | (242 | ) | ||||
Debt
required to be repaid upon sale of discontinued operations
|
(99 | ) |
-
-
|
|||||
Other
net cash provided by financing activities – discontinued
operations
|
23
|
5
|
||||||
Net
cash used in financing activities
|
(465 | ) | (237 | ) | ||||
Effect
of exchange rate changes on cash
|
1
|
2
|
||||||
Decrease
in cash and cash equivalents
|
(88 | ) | (179 | ) | ||||
Cash
and cash equivalents at beginning of period
|
121
|
279
|
||||||
Cash
and cash equivalents at end of period
|
33
|
100
|
||||||
Less:
Cash and cash equivalents at end of period – discontinued
operations
|
-
-
|
44
|
||||||
Cash
and cash equivalents at end of period – continuing
operations
|
$ |
33
|
$ |
56
|
1.
|
|
5
|
2.
|
|
5
|
3.
|
|
5
|
4.
|
|
6
|
5.
|
|
7
|
6.
|
|
8
|
7.
|
|
9
|
8.
|
|
9
|
9.
|
|
9
|
10.
|
|
10
|
11.
|
|
10
|
12.
|
|
11
|
13.
|
|
11
|
14.
|
|
12
|
15.
|
|
15
|
16.
|
|
15
|
17.
|
|
17
|
18.
|
|
17
|
Millions
of dollars
|
||||
Gross
sales proceeds
|
$ |
1,143
|
||
Cash
and cash equivalents sold
|
(37 | ) | ||
Costs
related to the sale
|
(17 | ) | ||
Net
proceeds from sale of discontinued operations
before
required repayment of debt
|
1,089
|
|||
Debt
required to be repaid
|
(99 | ) | ||
Net
proceeds from sale of discontinued operations
|
$ |
990
|
For
the three months ended
June
30,
|
For
the six months ended
June
30,
|
|||||||||||||||
Millions
of dollars
|
2007
|
2006
|
2007
|
2006
|
||||||||||||
Sales
and other operating revenues
|
$ |
181
|
$ |
357
|
$ |
514
|
$ |
696
|
||||||||
Gain
on sale of discontinued operations
|
$ |
337
|
$ |
-
-
|
$ |
337
|
$ |
-
-
|
||||||||
Other
income (loss) from discontinued operations
|
(2 | ) |
27
|
18
|
38
|
|||||||||||
Provision
for (benefit from) income taxes
|
52
|
(42 | ) |
58
|
(32 | ) | ||||||||||
Income
from discontinued operations,
net of tax
|
$ |
283
|
$ |
69
|
$ |
297
|
$ |
70
|
Millions
of dollars
|
December
31,
2006
|
|||
Cash
|
$ |
45
|
||
Inventories
|
353
|
|||
Other
current assets
|
263
|
|||
Total
current assets
|
661
|
|||
Property,
plant and equipment, net
|
522
|
|||
Goodwill,
net
|
55
|
|||
Other
noncurrent assets, net
|
117
|
|||
Total
long-term assets
|
694
|
|||
Total
assets
|
$ |
1,355
|
||
Current
maturities of long-term debt
|
$ |
4
|
||
Other
current liabilities
|
331
|
|||
Total
current liabilities
|
335
|
|||
Long-term
debt
|
82
|
|||
Other
noncurrent liabilities
|
239
|
|||
Minority
interest
|
40
|
|||
Total
long-term liabilities
|
361
|
|||
Total
liabilities
|
$ |
696
|
Millions
of dollars
|
June
30,
2007
|
December
31,
2006
|
||||||
BALANCE
SHEETS
|
||||||||
Total
current assets
|
$ |
2,111
|
$ |
2,158
|
||||
Property,
plant and equipment, net
|
2,812
|
2,846
|
||||||
Investments
and other assets, net
|
321
|
355
|
||||||
Total
assets
|
$ |
5,244
|
$ |
5,359
|
||||
Notes
payable – Millennium Chemicals Inc.
|
$ |
500
|
$ |
-
-
|
||||
Other
current liabilities
|
1,283
|
1,217
|
||||||
Long-term
debt
|
1,553
|
2,160
|
||||||
Other
liabilities and deferred revenues
|
384
|
378
|
||||||
Partners’
capital
|
1,524
|
1,604
|
||||||
Total
liabilities and partners’ capital
|
$ |
5,244
|
$ |
5,359
|
For
the three months ended
June
30,
|
For
the six months ended
June
30,
|
|||||||||||||||
Millions
of dollars
|
2007
|
2006
|
2007
|
2006
|
||||||||||||
STATEMENTS
OF INCOME
|
||||||||||||||||
Sales
and other operating revenues
|
$ |
3,534
|
$ |
3,278
|
$ |
6,403
|
$ |
6,314
|
||||||||
Cost
of sales
|
3,362
|
3,028
|
6,100
|
5,698
|
||||||||||||
Selling,
general and administrative expenses
|
72
|
61
|
131
|
109
|
||||||||||||
Research
and development expenses
|
9
|
9
|
18
|
17
|
||||||||||||
Operating
income
|
91
|
180
|
154
|
490
|
||||||||||||
Interest
expense, net
|
(50 | ) | (52 | ) | (103 | ) | (105 | ) | ||||||||
Other
expense, net
|
(33 | ) |
-
-
|
(32 | ) | (1 | ) | |||||||||
Net
income
|
$ |
8
|
$ |
128
|
$ |
19
|
$ |
384
|
Millions
of dollars
|
June
30,
2007
|
December
31,
2006
|
||||||
Finished
goods
|
$ |
62
|
$ |
63
|
||||
Work-in-process
|
19
|
15
|
||||||
Raw
materials
|
5
|
4
|
||||||
Materials
and supplies
|
6
|
5
|
||||||
Total
inventories
|
$ |
92
|
$ |
87
|
Millions
of dollars
|
June
30,
2007
|
December
31,
2006
|
||||||
Land
|
$ |
2
|
$ |
2
|
||||
Manufacturing
facilities and equipment
|
330
|
342
|
||||||
Construction
in progress
|
16
|
16
|
||||||
Total
property, plant and equipment
|
348
|
360
|
||||||
Less
accumulated depreciation
|
(227 | ) | (231 | ) | ||||
Property,
plant and equipment, net
|
$ |
121
|
$ |
129
|
For
the three months ended
June
30,
|
For
the six months ended
June
30,
|
|||||||||||||||
Millions
of dollars
|
2007
|
2006
|
2007
|
2006
|
||||||||||||
Property,
plant and equipment
|
$ |
10
|
$ |
4
|
$ |
14
|
$ |
9
|
||||||||
Other
|
1
|
2
|
3
|
4
|
||||||||||||
Total
depreciation and amortization
|
$ |
11
|
$ |
6
|
$ |
17
|
$ |
13
|
Millions
of dollars
|
June
30,
2007
|
December
31,
2006
|
||||||
Senior
Notes due 2008, 9.25%
|
$ |
-
-
|
$ |
375
|
||||
Senior
Debentures due 2026, 7.625%
|
241
|
245
|
||||||
Convertible
Senior Debentures due 2023, 4%
|
150
|
150
|
||||||
Other
|
-
-
|
(3 | ) | |||||
Total
|
391
|
767
|
||||||
Less
current maturities
|
-
-
|
-
-
|
||||||
Total
long-term debt, net
|
$ |
391
|
$ |
767
|
For
the three months ended
June
30,
|
For
the six months ended
June
30,
|
|||||||||||||||
Millions
of dollars
|
2007
|
2006
|
2007
|
2006
|
||||||||||||
Service
cost
|
$ |
1
|
$ |
1
|
$ |
2
|
$ |
2
|
||||||||
Interest
cost
|
8
|
8
|
16
|
16
|
||||||||||||
Recognized
return on plan assets
|
(9 | ) | (9 | ) | (18 | ) | (18 | ) | ||||||||
Amortization
|
1
|
4
|
4
|
8
|
||||||||||||
Net
periodic pension benefit cost
|
$ |
1
|
$ |
4
|
$ |
4
|
$ |
8
|
Millions
of dollars
|
2007
|
2006
|
||||||
Balance
at January 1
|
$ |
148
|
$ |
145
|
||||
Additional
provisions
|
10
|
4
|
||||||
Amounts
paid
|
(5 | ) | (5 | ) | ||||
Balance
at June 30
|
$ |
153
|
$ |
144
|
For
the three months ended
June
30,
|
For
the six months ended
June
30,
|
|||||||||||||||
Millions
of dollars
|
2007
|
2006
|
2007
|
2006
|
||||||||||||
Net
income
|
$ |
266
|
$ |
114
|
$ |
281
|
$ |
147
|
||||||||
Other
comprehensive income, net of tax:
|
||||||||||||||||
Continuing
operations:
|
||||||||||||||||
Foreign
currency translation
|
-
-
|
1
|
-
-
|
1
|
||||||||||||
Amortization
of actuarial and investment loss
included
in net periodic pension cost
|
3
|
-
-
|
3
|
-
-
|
||||||||||||
Discontinued
operations:
|
||||||||||||||||
Foreign
currency translation
|
7
|
8
|
16
|
23
|
||||||||||||
Amortization
of actuarial and investment loss
included
in net periodic pension cost
|
2
|
-
-
|
2
|
-
-
|
||||||||||||
Sale
of discontinued operations
|
(63 | ) |
-
-
|
(63 | ) |
-
-
|
||||||||||
Total
other comprehensive income
|
(51 | ) |
9
|
(42 | ) |
24
|
||||||||||
Comprehensive
income
|
$ |
215
|
$ |
123
|
$ |
239
|
$ |
171
|
·
|
Ethylene,
co-products and derivatives (“EC&D”), including Millennium’s acetyls
business, which produces vinyl acetate monomer (“VAM”), acetic acid and
methanol; and Millennium’s equity investment in Equistar, which produces
primarily ethylene, co-products such as propylene, butadiene and
aromatics, and derivatives such as ethylene oxide, ethylene glycol
and
polyethylene; and
|
·
|
Fragrance
and flavors chemicals, which includes terpene-based fragrance ingredients
and flavor ingredients.
|
Millions
of dollars
|
EC&D
|
Fragrance
& Flavors
|
Other
|
Total
|
||||||||||||
For
the three months ended June 30, 2007
|
||||||||||||||||
Sales
and other operating revenues
|
$ |
131
|
$ |
28
|
$ |
2
|
$ |
161
|
||||||||
Operating
income (loss)
|
15
|
2
|
(21 | ) | (4 | ) | ||||||||||
Income
from equity investment
|
3
|
-
-
|
-
-
|
3
|
||||||||||||
For
the three months ended June 30, 2006
|
||||||||||||||||
Sales
and other operating revenues
|
$ |
122
|
$ |
27
|
$ |
4
|
$ |
153
|
||||||||
Operating
income (loss)
|
9
|
2
|
(4 | ) |
7
|
|||||||||||
Income
from equity investment
|
38
|
-
-
|
-
-
|
38
|
||||||||||||
For
the six months ended June 30, 2007
|
||||||||||||||||
Sales
and other operating revenues
|
$ |
253
|
$ |
56
|
$ |
4
|
$ |
313
|
||||||||
Operating
income (loss)
|
36
|
5
|
(28 | ) |
13
|
|||||||||||
Income
from equity investment
|
6
|
-
-
|
-
-
|
6
|
||||||||||||
For
the six months ended June 30, 2006
|
||||||||||||||||
Sales
and other operating revenues
|
$ |
238
|
$ |
53
|
$ |
6
|
$ |
297
|
||||||||
Operating
income (loss)
|
1
|
3
|
(11 | ) | (7 | ) | ||||||||||
Income
from equity investment
|
113
|
-
-
|
-
-
|
113
|
BALANCE
SHEET
|
||||||||||||||||||||
As
of June 30, 2007
|
||||||||||||||||||||
Millions
of dollars
|
Millennium
Chemicals
Inc.
|
Millennium
America
Inc.
|
Non-Guarantor
Subsidiaries
|
Eliminations
|
Millennium
Chemicals
Inc.
and
Subsidiaries
|
|||||||||||||||
Inventories
|
$ |
-
-
|
$ |
-
-
|
$ |
92
|
$ |
-
-
|
$ |
92
|
||||||||||
Notes
receivable from
Equistar
Chemicals, LP
|
200
|
300
|
-
-
|
-
-
|
500
|
|||||||||||||||
Other
current assets
|
-
-
|
17
|
209
|
-
-
|
226
|
|||||||||||||||
Property,
plant and equipment, net
|
-
-
|
-
-
|
121
|
-
-
|
121
|
|||||||||||||||
Investment
in Equistar Chemicals, LP
|
-
-
|
-
-
|
446
|
-
-
|
446
|
|||||||||||||||
Investment
in subsidiaries
|
298
|
1,650
|
-
-
|
(1,948 | ) |
-
-
|
||||||||||||||
Goodwill,
net
|
-
-
|
-
-
|
49
|
-
-
|
49
|
|||||||||||||||
Other
assets, net
|
2
|
13
|
56
|
-
-
|
71
|
|||||||||||||||
Total
assets
|
$ |
500
|
$ |
1,980
|
$ |
973
|
$ | (1,948 | ) | $ |
1,505
|
|||||||||
Current
liabilities
|
$ |
1
|
$ |
2
|
$ |
251
|
$ |
-
-
|
$ |
254
|
||||||||||
Long-term
debt
|
150
|
241
|
-
-
|
-
-
|
391
|
|||||||||||||||
Other
liabilities
|
-
-
|
-
-
|
255
|
-
-
|
255
|
|||||||||||||||
Deferred
income taxes
|
-
-
|
-
-
|
261
|
-
-
|
261
|
|||||||||||||||
Due
to parent and affiliates, net
|
10
|
560
|
(570 | ) |
-
-
|
-
-
|
||||||||||||||
Total
liabilities
|
161
|
803
|
197
|
-
-
|
1,161
|
|||||||||||||||
Minority
interest
|
-
-
|
-
-
|
5
|
-
-
|
5
|
|||||||||||||||
Stockholder’s
equity
|
339
|
1,177
|
771
|
(1,948 | ) |
339
|
||||||||||||||
Total
liabilities
and stockholder’s equity
|
$ |
500
|
$ |
1,980
|
$ |
973
|
$ | (1,948 | ) | $ |
1,505
|
BALANCE
SHEET
|
||||||||||||||||||||
As
of December 31, 2006
|
||||||||||||||||||||
Millions
of dollars
|
Millennium
Chemicals
Inc.
|
Millennium
America
Inc.
|
Non-Guarantor
Subsidiaries
|
Eliminations
|
Millennium
Chemicals
Inc.
and
Subsidiaries
|
|||||||||||||||
Inventories
|
$ |
-
-
|
$ |
-
-
|
$ |
87
|
$ |
-
-
|
$ |
87
|
||||||||||
Other
current assets
|
-
-
|
62
|
200
|
-
-
|
262
|
|||||||||||||||
Current
assets held for sale
|
-
-
|
-
-
|
661
|
-
-
|
661
|
|||||||||||||||
Property,
plant and equipment, net
|
-
-
|
-
-
|
129
|
-
-
|
129
|
|||||||||||||||
Investment
in Equistar Chemicals, LP
|
-
-
|
-
-
|
470
|
-
-
|
470
|
|||||||||||||||
Investment
in subsidiaries
|
310
|
497
|
-
-
|
(807 | ) |
-
-
|
||||||||||||||
Goodwill,
net
|
-
-
|
-
-
|
49
|
-
-
|
49
|
|||||||||||||||
Other
assets, net
|
(2 | ) | (2 | ) |
66
|
-
-
|
62
|
|||||||||||||
Due
from parent and affiliates, net
|
-
-
|
368
|
-
-
|
(368 | ) |
-
-
|
||||||||||||||
Long-term
assets held for sale
|
-
-
|
-
-
|
694
|
-
-
|
694
|
|||||||||||||||
Total
assets
|
$ |
308
|
$ |
925
|
$ |
2,356
|
$ | (1,175 | ) | $ |
2,414
|
|||||||||
Current
liabilities
|
$ |
1
|
$ |
4
|
$ |
169
|
$ |
-
-
|
$ |
174
|
||||||||||
Current
liabilities associated
with
assets held for sale
|
-
-
|
-
-
|
335
|
-
-
|
335
|
|||||||||||||||
Long-term
debt
|
150
|
617
|
-
-
|
-
-
|
767
|
|||||||||||||||
Other
liabilities
|
-
-
|
3
|
378
|
-
-
|
381
|
|||||||||||||||
Deferred
income taxes
|
-
-
|
-
-
|
248
|
-
-
|
248
|
|||||||||||||||
Due
to parent and affiliates, net
|
14
|
-
-
|
354
|
(368 | ) |
-
-
|
||||||||||||||
Long-term
liabilities associated
with
assets held for sale
|
-
-
|
-
-
|
361
|
-
-
|
361
|
|||||||||||||||
Total
liabilities
|
165
|
624
|
1,845
|
(368 | ) |
2,266
|
||||||||||||||
Minority
interest
|
-
-
|
-
-
|
5
|
-
-
|
5
|
|||||||||||||||
Stockholder’s
equity
|
143
|
301
|
506
|
(807 | ) |
143
|
||||||||||||||
Total
liabilities and
stockholder’s equity
|
$ |
308
|
$ |
925
|
$ |
2,356
|
$ | (1,175 | ) | $ |
2,414
|
STATEMENT
OF INCOME
|
||||||||||||||||||||
For
the Three Months Ended June 30, 2007
|
||||||||||||||||||||
Millions
of dollars
|
Millennium
Chemicals
Inc.
|
Millennium
America
Inc.
|
Non-Guarantor
Subsidiaries
|
Eliminations
|
Millennium
Chemicals
Inc.
and
Subsidiaries
|
|||||||||||||||
Sales
and other operating revenues
|
$ |
-
-
|
$ |
-
-
|
$ |
161
|
$ |
-
-
|
$ |
161
|
||||||||||
Cost
of sales
|
-
-
|
-
-
|
142
|
-
-
|
142
|
|||||||||||||||
Selling,
general
and
administrative expenses
|
-
-
|
-
-
|
22
|
-
-
|
22
|
|||||||||||||||
Research
and development expenses
|
-
-
|
-
-
|
1
|
-
-
|
1
|
|||||||||||||||
Operating
loss
|
-
-
|
-
-
|
(4 | ) |
-
-
|
(4 | ) | |||||||||||||
Interest
expense, net
|
-
-
|
(10 | ) | (3 | ) |
-
-
|
(13 | ) | ||||||||||||
Intercompany
interest
income
(expense), net
|
-
-
|
28
|
(28 | ) |
-
-
|
-
-
|
||||||||||||||
Income
from equity investment in
Equistar
Chemicals, LP
|
-
-
|
-
-
|
3
|
-
-
|
3
|
|||||||||||||||
Equity
in
income
of subsidiaries
|
266
|
873
|
-
-
|
(1,139 | ) |
-
-
|
||||||||||||||
Other
income (expense), net
|
-
-
|
(17 | ) |
1
|
-
-
|
(16 | ) | |||||||||||||
Benefit
from
(provision
for) income taxes
|
-
-
|
(305 | ) |
318
|
-
-
|
13
|
||||||||||||||
Income
from discontinued
operations,
net of tax
|
-
-
|
-
-
|
283
|
-
-
|
283
|
|||||||||||||||
Net
income
|
$ |
266
|
$ |
569
|
$ |
570
|
$ | (1,139 | ) | $ |
266
|
STATEMENT
OF INCOME
|
||||||||||||||||||||
For
the Three Months Ended June 30, 2006
|
||||||||||||||||||||
Millions
of dollars
|
Millennium
Chemicals
Inc.
|
Millennium
America
Inc.
|
Non-Guarantor
Subsidiaries
|
Eliminations
|
Millennium
Chemicals
Inc.
and
Subsidiaries
|
|||||||||||||||
Sales
and other operating revenues
|
$ |
-
-
|
$ |
-
-
|
$ |
153
|
$ |
-
-
|
$ |
153
|
||||||||||
Cost
of sales
|
-
-
|
-
-
|
134
|
-
-
|
134
|
|||||||||||||||
Selling,
general
and
administrative expenses
|
-
-
|
-
-
|
11
|
-
-
|
11
|
|||||||||||||||
Research
and development expenses
|
-
-
|
-
-
|
1
|
-
-
|
1
|
|||||||||||||||
Operating
income
|
-
-
|
-
-
|
7
|
-
-
|
7
|
|||||||||||||||
Interest
expense, net
|
(1 | ) | (15 | ) | (2 | ) |
-
-
|
(18 | ) | |||||||||||
Intercompany
interest
income
(expense), net
|
-
-
|
27
|
(27 | ) |
-
-
|
-
-
|
||||||||||||||
Other
income, net
|
-
-
|
-
-
|
20
|
-
-
|
20
|
|||||||||||||||
Income
from equity investment in
Equistar Chemicals,
LP
|
-
-
|
-
-
|
38
|
-
-
|
38
|
|||||||||||||||
Equity
in income of subsidiaries
|
115
|
18
|
(54 | ) | (79 | ) |
-
-
|
|||||||||||||
Benefit
from
(provision)
for income taxes
|
-
-
|
16
|
(18 | ) |
-
-
|
(2 | ) | |||||||||||||
Income
from discontinued
operations,
net of tax
|
-
-
|
-
-
|
69
|
-
-
|
69
|
|||||||||||||||
Net
income
|
$ |
114
|
$ |
46
|
$ |
33
|
$ | (79 | ) | $ |
114
|
STATEMENT
OF INCOME
|
||||||||||||||||||||
For
the Six Months Ended June 30, 2007
|
||||||||||||||||||||
Millions
of dollars
|
Millennium
Chemicals
Inc.
|
Millennium
America
Inc.
|
Non-Guarantor
Subsidiaries
|
Eliminations
|
Millennium
Chemicals
Inc.
and
Subsidiaries
|
|||||||||||||||
Sales
and other operating revenues
|
$ |
-
-
|
$ |
-
-
|
$ |
313
|
$ |
-
-
|
$ |
313
|
||||||||||
Cost
of sales
|
-
-
|
-
-
|
264
|
-
-
|
264
|
|||||||||||||||
Selling,
general
and
administrative expenses
|
-
-
|
-
-
|
34
|
-
-
|
34
|
|||||||||||||||
Research
and development expenses
|
-
-
|
-
-
|
2
|
-
-
|
2
|
|||||||||||||||
Operating
income
|
-
-
|
-
-
|
13
|
-
-
|
13
|
|||||||||||||||
Interest
expense, net
|
(4 | ) | (23 | ) | (4 | ) |
-
-
|
(31 | ) | |||||||||||
Intercompany
interest
income
(expense), net
|
-
-
|